Day: June 24, 2025

Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC HOUSTON, June 24, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces a comprehensive restructuring of its previous $15 million equity financing announced on March 4, 2025. This strategic restructuring eliminates potential dilution of up to 1.5 billion shares of common stock, which the Company believes will significantly enhance shareholder value and position the Company to move forward with a more straightforward equity capital structure. KEY...

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days’ Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. “We are proud to support Good Days with this unprecedented philanthropic effort,” said Leonard Schleifer, M.D., Ph.D., Board Co-Chair, President...

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | OTCQB: NKOSF | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce the appointment of Ryan Weston as Vice President Exploration of the Company. Ryan brings over 20 years of global experience in base and precious metals exploration to the Company. He played key roles in the successful sale of Carlisle Goldfields to Alamos Gold for CAD $28 million in 2016, and of Noront Resources to Wyloo Metals for CAD $686 million in 2022. Most recently, he served as Vice President Exploration at Wyloo, where he led exploration initiatives in Ontario’s Ring of Fire region. Ryan is a registered P.Geo. in Ontario and holds an MBA from Queen’s University, an M.Sc. from Laurentian University, and a B.Sc. from the University of Toronto. “I am thrilled to be joining...

NEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Douglas B. Kirsch, M.D., FAAN, FAASM to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. “We are honored to welcome Dr. Kirsch to the IHL-42X Clinical Advisory Board,” stated Dr. Lou Barbato, Incannex Chief Medical Officer. “His extensive clinical experience and leadership within the sleep medicine community will be instrumental as we advance IHL-42X through late-stage development. With his addition, our advisory board continues to strengthen its depth of expertise at a pivotal time for the program.” Dr. Kirsch is a recognized authority in...

Ships Backlog of 800G Optical Engine Samples to Customers TORONTO, June 24, 2025 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Corporation”) (TSX Venture: PTK; NASDAQ: POET), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced that it has signed a Master Agreement, Module Purchase Agreement and a Deed of Consignment with NationGate Solutions (M) Sdn. Bhd (“NationGate”), to manufacture optical engine assemblies for POET in Penang, Malaysia. POET has engaged with NationGate to assemble and test consigned optical engines with a custom-designed fiber-attach unit (FAU) made specifically for one of POET’s key customers. That customer has confirmed a high level of interest from hyperscale data centers in a product that includes...

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction (DDI) studies, to certify impurities are below the Acceptable Intake (AI) Limit set by U.S. Food and Drug Administration (FDA) guidelines. Fortrea has selected Emery Pharma due to its strong capabilities...

Volta Finance Limited (VTA / VTAS)May 2025 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, June 24, 2025 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for May 2025. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). Performance and Portfolio Activity Dear Investors, In May, Volta Finance’s net performance reached +3.3% bringing the performance from August 2024 to date to +10.7%. Our investments in CLO Debt and CLO Equity recovered some of their post-liberation day volatility due to improved market sentiment. May saw a more positive macroeconomic environment, helping markets recover most of the losses from the previous month. The 90-day tariff...

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute to Specialty & Primary Care growth in coming years Milan, 24 June 2025 – Recordati today announced a licensing and supply agreement with Amarin to commercialize the marketed cardiovascular medicine, Vazkepa® (icosapent ethyl) across 59 countries, focused in Europe. Vazkepa® is indicated to reduce the risk of cardiovascular events in statin-treated adult patients at high cardiovascular risk with elevated triglycerides and either established cardiovascular disease or diabetes with at least one other cardiovascular risk factor. Vazkepa® was approved in 2021 in the EU and UK and in 2022 in Switzerland based on the REDUCE-IT study, a Phase 3 Cardiovascular...

ALBUQUERQUE, N.M., June 24, 2025 (GLOBE NEWSWIRE) — Array Technologies, Inc. (NASDAQ: ARRY) (the “Company” or “ARRAY”) today announced that, subject to market conditions, it intends to offer $250 million in aggregate principal amount of convertible senior notes due 2031 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). ARRAY also intends to grant the initial purchasers of the Notes an option to purchase, for settlement within a 13-day period from, and including the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of Notes. The Notes will be senior, unsecured obligations of ARRAY, and will accrue interest payable semiannually...

OTTAWA, Ontario, June 24, 2025 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and strategic growth critical infrastructure sectors, today announced that Chris Pogue will join the company as President, Defence & Space, effective July 7, 2025. In this newly created role, Pogue will lead a high-performance organization that brings together Calian’s Advanced Technologies and Learning business units—leveraging the synergies of its communications and manufacturing solutions alongside its immersive training and simulation expertise to accelerate mission success for defence and space customers alike. “Chris Pogue is one of Canada’s most accomplished leaders in defence and space innovation,” said Kevin Ford, CEO of Calian. “His track record—growing Thales...